APA (7th ed.) Citation

Bang, Y., Karayama, M., Takahashi, M., Watanabe, J., Minami, H., Yamamoto, N., . . . Takahashi, S. (2019). 330P - Pharmacokinetics (PK), safety, and efficacy of [fam-] trastuzumab deruxtecan with OATP1B/CYP3A inhibitors in subjects with HER2-expressing advanced solid tumours. Annals of oncology, 30, v116-v117. https://doi.org/10.1093/annonc/mdz242.025

Chicago Style (17th ed.) Citation

Bang, Y.-J, et al. "330P - Pharmacokinetics (PK), Safety, and Efficacy of [fam-] Trastuzumab Deruxtecan with OATP1B/CYP3A Inhibitors in Subjects with HER2-expressing Advanced Solid Tumours." Annals of Oncology 30 (2019): v116-v117. https://doi.org/10.1093/annonc/mdz242.025.

MLA (9th ed.) Citation

Bang, Y.-J, et al. "330P - Pharmacokinetics (PK), Safety, and Efficacy of [fam-] Trastuzumab Deruxtecan with OATP1B/CYP3A Inhibitors in Subjects with HER2-expressing Advanced Solid Tumours." Annals of Oncology, vol. 30, 2019, pp. v116-v117, https://doi.org/10.1093/annonc/mdz242.025.